Amplatzer Amulet LAA Occluder Will be Compared to Anticoagulants in CATALYST Trial

Feb 3, 2020 | EP Lab Digest

The U.S. Food and Drug Administration (FDA) has approved a the CATALYST trial designed to assess Abbott’s Amplatzer Amulet left atrial appendage (LAA) occluder for people with atrial fibrillation (AF or AFib).

X